A double-blind, parallel group, comparative study of coadministration AD-4833 and SYR-322
Phase 4
- Conditions
- Diabetes mellitus
- Registration Number
- JPRN-jRCT1080221871
- Lead Sponsor
- TAKEDA PHARMACEUTICAL COMPANY LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.
Exclusion Criteria
Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
Others who are assessed to be ineligible for the study by the investigator or subinvestigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method